A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-23. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
== Structure == Most sv-LAAOs are reported as being homodimers with multiple subunits that have molecular weights around 50–70 kDa and the interaction between the subunits occurs via non-covalent interactions. Sv-LAAOs are present in the acidic, basic, and neutral forms of the protein. Studies that look at x-ray crystal structures have confirmed that sv-LAAOs are often found as functional dimers, with each dimer having three domains. The three domains are the substrate-binding site, FAD-binding site, and a helical domain. The substrate-binding site lies at the bottom of a funnel-shaped cavity approximately 25 Å deep, enabling substrate specificity among sv-LAAOs. Structural differences in active site topology likely account for species-dependent substrate preferences. Additionally, LAAOs are thermolabile, with cold inactivation and heat reactivation properties, necessitating specific storage and pre-activation conditions to preserve enzymatic activity. It has also been determined that the FAD prosthetic group becomes deeply entrenched in the enzyme structure, which allows for pervasive interactions with both neighboring atoms and conserved water molecules. Additionally, this flavin-containing prosthetic group has been classified as providing snake venom with its quintessential dark yellow coloration, which is shown in Figure 2. One unusual characteristic reported for sv-LAAOs regards the cold inactivation and heat reactivation properties of the protein. Thereby, most sv-LAAOs are considered to be thermolabile enzymes.
The concentrations of species in equilibrium are usually calculated under the assumption that activity coefficients are either known or can be ignored. In this case, each equilibrium constant for the formation of a complex in a set of multiple equilibria can be defined as follows
In the chemical industry, carbon dioxide is mainly consumed as an ingredient in the production of urea, with a smaller fraction being used to produce methanol and a range of other products. Some carboxylic acid derivatives such as sodium salicylate are prepared using CO2 by the Kolbe–Schmitt reaction. Captured CO2 could be to produce methanol or electrofuels. To be carbon-neutral, the CO2 would need to come from bioenergy production or direct air capture.
In the U.S., the Food and Drug Administration (FDA) must approve a substance as a drug before it can be marketed. The approval process involves several steps including pre-clinical laboratory and animal studies, clinical trials for safety and efficacy, filing of a New Drug Application by the manufacturer of the drug, FDA review of the application, and FDA approval/rejection of application (NLM) Arm
Sources: en.wikipedia.org
== Characteristics == The leaves, known as tējapattā or tejpattā (तेजपत्ता) in Hindi, tejpāt (तेजपात/তেজপাত) in Nepali, Maithili, and Assamese, tejpātā (তেজপাতা) in Bengali, vazhanayila/edanayila (വഴനയില/എടനഇല) in Malayalam, kaḍu dhālchini (kn:ಕಾಡು ದಾಲ್ಚಿನ್ನಿ) in Kannada, tamalpatra (તમલપત્ર) in Gujarati, and tamālpatra (तमालपत्र) in Marathi and in original Sanskrit, are used extensively in the cuisines of India, Nepal, and Bhutan, particularly in the Mughlai cuisine of North India and Nepal and in tsheringma herbal tea in Bhutan. They are called biryāni āku/baghāra āku (బిర్యానీ ఆకు/బగార ఆకు) in Telugu and tejåpåtrå/tejåpåtårå (ତେଜପତ୍ର/ତେଜପତର) in Odia. The Lepcha of Sikkim call them naap saor koong.
For services to People with Dementia and their Families. Dr. Emma Lucy Wilson. Director of Technical, Production and Costume, Royal Opera House. For services to the Performing Arts. William Wilson. Senior Officer, National Crime Agency. For services to Law Enforcement. Belinda Ann Winstone. Team Leader, Army Bereavement and Aftercare Services. For services to Military Families. Joan Harris Winterkorn. Archive and Manuscript Consultant and Member, Acceptance in Lieu Panel, Arts Council England. For services to Heritage and Culture. Theresa Wise. Chief Executive, Royal Television Society. For services to Broadcasting. Nicola Clare Wood. Senior Independent Director, Information Commissioner's Office. For services to Regulation. Mary Elizabeth Woods. Lately Nurse Consultant, The Royal Marsden NHS Foundation Trust. For services to Lymphoedema. Caroline Valerie Wright. Early Childhood Director, Bright Horizons Nursery. For services to Early Years Education. Judith Kathleen Wright. Trustee, Orders of St John Care Trust and lately Chair, St John Priory Group for Buckinghamshire. For voluntary service to the Order of St John. Stephen Richard Wright. Broadcaster. For services to Radio. Gloria Ingrid Wyse. Head of Research and Content, Business in the Community. For services to Diversity and Inclusion. Dr. Richard Kenneth Howard Wyse. Director of Clinical Development, Cure Parkinson's. For services to Medicine in Parkinson's Disease. Susan Yates. Officer, National Crime Agency. For services to Law Enforcement. Allan Reid Young. Head of Instrumental Music, Perth and Kinross.
== Products == The JEOL AccuTOF JMS T100LC mass spectrometer won a bronze award at the 2002 Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy The DART ion source won a Pittcon Editors' Gold Award at the 2005 Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy maskless lithograph ML2 type, JBX-8100FS, based on patented ZrO/W (Schottky) emitter.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.